Scholarlink

<p>Alopecia areata (AA) is an autoimmune condition characterized by non-scarring hair loss on the scalp, face, and body, affecting approximately 2% of the global population. Current treatments, including topical corticosteroids, topical immunotherapies, and systemic immunosuppressants, often demonstrate inconsistent efficacy and raise concerns about long-term safety, emphasizing the need for safer and more effective therapies. Janus kinase (JAK) inhibitors have emerged as a promising treatment option, offering a targeted approach by addressing the immune-mediated mechanisms driving hair follicle destruction in AA. Recent clinical advances have led to FDA approval of three JAK inhibitors—baricitinib, ritlecitinib, and deuruxolitinib—based on pivotal trials showing significant hair regrowth. Baricitinib has demonstrated durable efficacy, with 35–40% of patients achieving a Severity of Alopecia Tool (SALT) score ≤ 20 at 36&#xa0;weeks. Ritlecitinib similarly reported 23% of patients achieving a SALT score ≤ 20 at week 24. Deuruxolitinib has also shown efficacy with 31% of patients achieving a SALT score ≤ 20 at 24&#xa0;weeks. Off-label use of JAK inhibitors like tofacitinib and ruxolitinib have also demonstrated efficacy in limited studies. This review aims to consolidate and summarize the latest clinical evidence and trial data on JAK inhibitors for AA, providing an up-to-date resource for clinicians and researchers to guide evidence-based management and optimize therapeutic outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Evaluating Current and Emergent JAK Inhibitors for Alopecia Areata: A Narrative Review

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月12日

查看全文
  • Katherine Sanchez,
  • Hanna Englander,
  • Lana Salloum,
  • Samantha Gregoire,
  • Ursula Biba,
  • Sherry Ershadi,
  • Arash Mostaghimi

摘要

Alopecia areata (AA) is an autoimmune condition characterized by non-scarring hair loss on the scalp, face, and body, affecting approximately 2% of the global population. Current treatments, including topical corticosteroids, topical immunotherapies, and systemic immunosuppressants, often demonstrate inconsistent efficacy and raise concerns about long-term safety, emphasizing the need for safer and more effective therapies. Janus kinase (JAK) inhibitors have emerged as a promising treatment option, offering a targeted approach by addressing the immune-mediated mechanisms driving hair follicle destruction in AA. Recent clinical advances have led to FDA approval of three JAK inhibitors—baricitinib, ritlecitinib, and deuruxolitinib—based on pivotal trials showing significant hair regrowth. Baricitinib has demonstrated durable efficacy, with 35–40% of patients achieving a Severity of Alopecia Tool (SALT) score ≤ 20 at 36 weeks. Ritlecitinib similarly reported 23% of patients achieving a SALT score ≤ 20 at week 24. Deuruxolitinib has also shown efficacy with 31% of patients achieving a SALT score ≤ 20 at 24 weeks. Off-label use of JAK inhibitors like tofacitinib and ruxolitinib have also demonstrated efficacy in limited studies. This review aims to consolidate and summarize the latest clinical evidence and trial data on JAK inhibitors for AA, providing an up-to-date resource for clinicians and researchers to guide evidence-based management and optimize therapeutic outcomes.